1. Resource table {#s0005}
=================

Name of stem cell lineKCL033InstitutionKing\'s College London, London, UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: <dusko.ilic@kcl.ac.uk>Date archived/stock dateAug 17, 2011Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature (direct URL links and full references)1)Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D., 2013. Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. EMBO Mol. Med. 5 (1), 10--17.doi: 10.1002/emmm.201201973 <http://www.ncbi.nlm.nih.gov/pubmed/23161805>\
2)Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P., Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J., Moore, H.D., Murray, H., Kunath, T., 2015. The molecular karyotype of 25 clinical-grade human embryonic stem cells lines. *Sci. Rep.* 5, 17258.doi: 10.1038/srep17258\
<http://www.ncbi.nlm.nih.gov/pubmed/26607962>\
3)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122--128.doi: 10.3109/14653249.2011.623692\
<http://www.ncbi.nlm.nih.gov/pubmed/22029654>\
4)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366--1381.doi: 10.1038/nprot.2012.080 <http://www.ncbi.nlm.nih.gov/pubmed/22722371>\
5)Devito, L., Petrova, A., Miere, C., Codognottom S., Blakely, N., Lovatt, A., Ogilvie, C., Khalaf, Y., Ilic, D., 2014. Cost-effective master cell bank validation of multiple clinical-grade human pluripotent stem cell lines from a single donor. Stem Cells Transl. Med. 3(10), 1116--1124. doi: 10.5966/sctm.2014-0015 <http://www.ncbi.nlm.nih.gov/pubmed/25122690>Information in public databasesKCL033 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: NIHhESC-14-0267\
<http://grants.nih.gov/stem_cells/registry/current.htm?id=653>EthicsThe hESC line KCL033 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

Resource details {#s0010}
================

Consent signedMay 26, 2009Embryo thawedJul 11, 2011UK stem cell bank deposit approvalMar 08, 2012\
Reference: SCSC12-54SexFemale 46, XXGradeClinicalDisease statusHealthy/UnaffectedKaryotype (aCGH)No copy number changes detected.SNP arrayGain in regions 5p14.3 and 12p11.21 ([@bb0005])DNA fingerprintAllele sizes (in bp) of 16 microsatellite markers specific for chromosomes 13, 18 and 21 ([@bb0040])HLA typingHLA-A 11,29; B 44,51; Bw 4; C 04,16; DRB1 04,07; DRB4 01; DQB1 02,03 ([@bb0040], [@bb0005])Viability testingPassMycoplasmaNegativeSterilityPassPluripotent markers\
(immunostaining)\
([Fig. 1](#f0005){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81Three germ layers differentiation in vitro\
(immunostaining)\
([Fig. 2](#f0010){ref-type="fig"})Endoderm: AFP\
Ectoderm: TUBB3 (tubulin, beta 3 class III)\
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)Sibling lines availableKCL032, KCL034

We generated KCL033 clinical grade hESC line following protocols, established previously ([@bb0035], [@bb0050]), and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after freeze/thaw cycle ([Fig. 1](#f0005){ref-type="fig"}). Differentiation potential into three germ layers was verified in vitro ([Fig. 2](#f0010){ref-type="fig"}).

Molecular karyotyping identified a novel 2.4 Mb gain on chromosome 5p14.3 and a gain on chromosome 12p11.21, which was also found in KCL040.

The gain on chromosome 5p14.3 containing a single gene, *CDH18* (Cadherin-18), was also present in one of two sibling cell lines, KCL032, but not in KCL034, a third sibling. A duplication of this size has not been reported to date, but its presence in two sibling hESC lines strongly suggests that it was inherited from one of the parents rather than by acquisition during hESC derivation and culture ([@bb0005]). The 2498.8 bp gain starts at bp 19086546 and ends at bp 21585311 as referred to Human Genome Build 38.

The gain on chromosome 12p11.21 contains no genes and it has been also reported in at least 14 submissions at Database of Genomic Variants (DGV; <http://dgv.tcag.ca>), which has collected structural variations in more than 14,000 healthy individuals from worldwide population ([@bb0045]). Estimated frequency in the human population is 4.70% ([@bb0005]).

Validation for sterility and specific and non-specific human pathogens ([@bb0010]) conformed that the cells in the Master Bank were sterile, mycoplasma-free, and negative for *Treponema pallidum*, chlamydia, *Neisseria gonorrhoeae*, human immunodeficiency virus-1 and 2 (HIV-1 and -2), human T-lymphotropic virus types-1 and 2 (HTLV-1 and 2), hepatitis A, B and C (HAV, HBV and HCV), human herpes simplex virus HHV-4 (Epstein--Barr virus, EBV), -6, -7, and -8, human cytomegalovirus (hCMV), human parvovirus B19, SV40, JCV, BKV, enterovirus, HAV, HCV, nonspecific viral and other adventitious contaminants.

We also generated research grade of KCL033 line that is adapted to feeder-free conditions.

Materials and methods {#s0015}
=====================

Consenting process {#s0020}
------------------

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (FRO-V.6) were created on Dec. 18, 2008. HFEA Code of Practice that was in effect at the time of document creation: Edition 7 --- R.4 (<http://www.hfea.gov.uk/2999.html>). The donor couple signed the consent on May 26, 2009. HFEA Code of Practice that was in effect at the time of donor signature: Edition 7 --- R.4. HFEA Code of Practice Edition 7 --- R.4 was in effect: 02 Oct. 2008--30 Sep. 2009.

Embryo culture and micromanipulation {#s0025}
------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in detail ([@bb0035], [@bb0050]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

Cell culture {#s0030}
------------

ICM plated on mitotically inactivated HFF were cultured as described ([@bb0035], [@bb0050]). TE cells were removed mechanically from the outgrowth ([@bb0025], [@bb0030]). hES colonies were expanded and cryopreserved at the third passage.

Viability test {#s0035}
--------------

Straws with the earliest frozen passage (p. 2--3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were part frozen and part subjected to standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, mycoplasma).

Pluripotency markers {#s0040}
--------------------

Pluripotency was assessed with immunostaining for pluripotency markers as described ([@bb0035], [@bb0050]).

Differentiation {#s0045}
---------------

Spontaneous differentiation into three germ layers was assessed in vitro and in vivo as described ([@bb9000], [@bb0050]).

Genotyping {#s0050}
----------

DNA was extracted from hES cell cultures using a Chemagen DNA extraction robot according to the manufacturer\'s instructions. Amplification of polymorphic microsatellite markers was carried out as described ([@bb0035]). Allele sizes were recorded to give a unique fingerprint of each cell line.

Array comparative genomic hybridization (aCGH) {#s0055}
----------------------------------------------

aCGH was performed as described in detail ([@bb0035]).

Whole-genome single nucleotide polymorphism (SNP) array {#s0060}
-------------------------------------------------------

SNP array was performed as described in detail ([@bb0005]).

HLA typing {#s0065}
----------

HLA-A, -B and -DRB1 typing was performed with a PCR sequence-specific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy\'s and St Thomas\' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy\'s Hospital, London, UK) as described ([@bb0040]). HLA typing was also performed independently by other group ([@bb0005]).

Validation for sterility and specific and non-specific human pathogens {#s0070}
----------------------------------------------------------------------

Validation for sterility and specific and non-specific human pathogens was performed as described ([@bb0010]). All validation studies were conducted by SGS Vitrology (Glasgow, U.K., <http://www.sgs.com>), in compliance with the principles of GMP as set out in Directive 2003/94/EC for medicinal products for human use ([@bb0015]) and 91/412/EEC for veterinary medicinal products ([@bb0020]).

Sterility testing was performed in accordance with the current requirements of the European Pharmacopoeia, Section 2.6.1 Sterility, U.S. Pharmacopeia, 71. Sterility Tests, and International Conference on Harmonisation Topic Q5D guidelines.

Mycoplasma testing was performed in accordance with the current requirements of the European Pharmacopoeia, Section 2.6.7, Mycoplasmas.

All PCR-based assays used were compliant with the current edition of the European Pharmacopoeia, 2.6.21, Nucleic Acid Amplification Techniques.

Author disclosure statement {#s0075}
===========================
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![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct. 4, Nanog, TRA-1-60, TRA-1-81). Scale bar, 50 μm.](gr1){#f0005}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.](gr2){#f0010}
